Seven-month study in pediatric patients (2-11 years) with moderate to severe AD who were considered to benefit from vaccination to prevent invasive disease caused by Neisseria meningitides serogroup C.
At the week 1 visit, the patients were vaccinated with a protein-conjugated vaccine against meningitis. All patients received a challenge at the month 6 visit with a low dose of meningo polysaccharide vaccine. A control group of healthy subjects (not suffering from atopic dermatitis) received only the vaccination and the challenge dose.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
260
topical application
topical application
topical application
Unnamed facility
Kogarah, New South Wales, Australia
Percentage of patients with serum bactericidal antibody titer of ≥ 8
Time frame: 5 weeks
Assessment of other immunological parameters
Time frame: 7 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
im injection
im injection
Unnamed facility
St Leonards, New South Wales, Australia
Unnamed facility
Benowa, Queensland, Australia
Unnamed facility
Carina Heights, Queensland, Australia
Unnamed facility
Herston, Queensland, Australia
Unnamed facility
North Adelaide, South Australia, Australia
Unnamed facility
Carlton, Victoria, Australia
Unnamed facility
Parkville, Victoria, Australia
Unnamed facility
Fremantle, Western Australia, Australia
Unnamed facility
Leuven, Belgium
...and 26 more locations